Avalyn Pharma Inc. reported the first quarter ended March 31, 2026 results: net income Net loss was $26.9 million.
“Avalyn Pharma Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2026.”
Avalyn Pharma Inc. — fact timeline
Source-grounded facts extracted from Avalyn Pharma Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Avalyn Pharma Inc.: Adopted amended and restated bylaws establishing stockholder meeting procedures, advance notice for proposals and director nominations, and conforming to charter amendments.
“the amended and restated bylaws of the Company (the “Amended and Restated Bylaws”), previously approved by the Board and the Company’s stockholders to become effective immediately upon effectiveness of the Registration Statement, became effective.”
Avalyn Pharma Inc.: Filed amended and restated certificate of incorporation to authorize 700M shares of common stock (500M voting, 200M non-voting), eliminate references to prior preferred stock series, and authorize 10M shares of undesignated preferred stock.
“the Company filed an amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.